Literature DB >> 18632156

Cloning, expression, and characterization of a single-domain antibody fragment with affinity for 15-acetyl-deoxynivalenol.

Patrick J Doyle1, Mehdi Arbabi-Ghahroudi, Nathalie Gaudette, Gordon Furzer, Marc E Savard, Steve Gleddie, Michael D McLean, C Roger Mackenzie, J Christopher Hall.   

Abstract

A single-domain variable heavy chain (V(H)H) antibody fragment specific to the mycotoxin 15-acetyldeoxynivalenol (15-AcDON) was obtained after immunization of a llama (Llama glama) with the protein conjugate 15-DON-BSA plus TiterMax Classic adjuvant. After confirmation of a polyclonal response to DON toxin in both conventional (cIgG) and heavy chain antibody (HCAb) fractions, a V(H)H library was constructed from amplified cDNA by nested PCR. V(H)H fragments with binding affinity for the mycotoxin were selected by panning of the phagemid library against microtiter plates coated with 15-DON-OVA. The dominant clone (NAT-267) was expressed in E. coli and was purified as a V(H)H monomer (mNAT-267) at a final concentration of 1.3 mg mL(-1). Isolated NAT-267 V(H)H DNA was fused to the homopentamerization domain of the B subunit of verotoxin to generate the pentabody format of single-domain antibody (sAb). The V(H)H pentamer (pNAT-267) was expressed in E. coli and was purified at a final concentration of 1.0 mg mL(-1). Surface plasmon resonance (SPR) analysis of soluble mNAT-267 binding kinetics to immobilized 15-DON-Horse Radish Peroxidase (HRP) indicated a dissociation constant (K(D)) of 5microM. Competitive direct enzyme-linked immunosorbent assay (CD-ELISA) and fluorescence polarization assay (FPA) inhibition experiments with monomer and pentamer confirmed binding to 15-AcDON. Competitive inhibition FPAs with mNAT-267 and pNAT-267 determined IC(50) values of 1.24 and 0.50 microM, respectively, for 15-AcDON hapten. These values were similar to the IC(50) value of 1.42 microM for 15-AcDON given by polyclonal llama serum sampled 56 days after immunization. Competition formats for structurally related trichothecenes resulted in no cross-reactivity to: DON; 3-acetyldeoxynivalenol (3-AcDON); neosolaniol (NEO); diacetoxyscirpenol (DAS); and T-2 toxin. Our study confirmed that recombinant V(H)H fragments capable of binding low molecular weight haptens can be produced through the creation and panning of hyper-immunized single-domain (sdAb) libraries.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632156     DOI: 10.1016/j.molimm.2008.06.005

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  25 in total

1.  Isolation of alpaca anti-hapten heavy chain single domain antibodies for development of sensitive immunoassay.

Authors:  Hee-Joo Kim; Mark R McCoy; Zuzana Majkova; Julie E Dechant; Shirley J Gee; Sofia Tabares-da Rosa; Gualberto G González-Sapienza; Bruce D Hammock
Journal:  Anal Chem       Date:  2011-12-29       Impact factor: 6.986

2.  An anti-hapten camelid antibody reveals a cryptic binding site with significant energetic contributions from a nonhypervariable loop.

Authors:  Sean W Fanning; James R Horn
Journal:  Protein Sci       Date:  2011-05-23       Impact factor: 6.725

3.  Competitive selection from single domain antibody libraries allows isolation of high-affinity antihapten antibodies that are not favored in the llama immune response.

Authors:  Sofia Tabares-da Rosa; Martin Rossotti; Carmen Carleiza; Federico Carrión; Otto Pritsch; Ki Chang Ahn; Jerold A Last; Bruce D Hammock; Gualberto González-Sapienza
Journal:  Anal Chem       Date:  2011-08-29       Impact factor: 6.986

4.  Neutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domain.

Authors:  Greg Hussack; Mehdi Arbabi-Ghahroudi; Henk van Faassen; J Glenn Songer; Kenneth K-S Ng; Roger MacKenzie; Jamshid Tanha
Journal:  J Biol Chem       Date:  2011-01-07       Impact factor: 5.157

5.  Intracellular expression of a single domain antibody reduces cytotoxicity of 15-acetyldeoxynivalenol in yeast.

Authors:  Patrick J Doyle; Hanaa Saeed; Anne Hermans; Steve C Gleddie; Greg Hussack; Mehdi Arbabi-Ghahroudi; Charles Seguin; Marc E Savard; C Roger Mackenzie; J Christopher Hall
Journal:  J Biol Chem       Date:  2009-09-25       Impact factor: 5.157

6.  Molecular imaging of glioblastoma multiforme using anti-insulin-like growth factor-binding protein-7 single-domain antibodies.

Authors:  U Iqbal; H Albaghdadi; Y Luo; M Arbabi; C Desvaux; T Veres; D Stanimirovic; A Abulrob
Journal:  Br J Cancer       Date:  2010-10-19       Impact factor: 7.640

Review 7.  VHH antibodies: emerging reagents for the analysis of environmental chemicals.

Authors:  Candace S Bever; Jie-Xian Dong; Natalia Vasylieva; Bogdan Barnych; Yongliang Cui; Zhen-Lin Xu; Bruce D Hammock; Shirley J Gee
Journal:  Anal Bioanal Chem       Date:  2016-05-21       Impact factor: 4.142

8.  In vivo neutralization of botulinum neurotoxins serotype E with heavy-chain camelid antibodies (VHH).

Authors:  Hamid Bakherad; Seyed Latif Mousavi Gargari; Iraj Rasooli; Masoumeh Rajabibazl; Mohammad Mohammadi; Walead Ebrahimizadeh; Leila Safaee Ardakani; Hamed Zare
Journal:  Mol Biotechnol       Date:  2013-10       Impact factor: 2.695

Review 9.  Single domain antibodies: promising experimental and therapeutic tools in infection and immunity.

Authors:  Janusz Wesolowski; Vanina Alzogaray; Jan Reyelt; Mandy Unger; Karla Juarez; Mariela Urrutia; Ana Cauerhff; Welbeck Danquah; Björn Rissiek; Felix Scheuplein; Nicole Schwarz; Sahil Adriouch; Olivier Boyer; Michel Seman; Alexei Licea; David V Serreze; Fernando A Goldbaum; Friedrich Haag; Friedrich Koch-Nolte
Journal:  Med Microbiol Immunol       Date:  2009-06-16       Impact factor: 3.402

10.  Development of a monoclonal antibody against deoxynivalenol for magnetic nanoparticle-based extraction and an enzyme-linked immunosorbent assay.

Authors:  Hyuk-Mi Lee; Sung-Ok Song; Sang-Ho Cha; Sung-Bok Wee; Karyn Bischoff; Sung-Won Park; Seong-Wan Son; Hwan-Goo Kang; Myung-Haing Cho
Journal:  J Vet Sci       Date:  2013-02-05       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.